Business
Vertex Pharmaceuticals Announces Key Business Objectives for 2006 at 24th Annual JPMorgan Healthcare Conference
Vertex Pharmaceuticals Announces Key Business Objectives for 2006 at 24th Annual JPMorgan Healthcare Conference.
About this update from Vortex Energy Corp.
[{"type":"text","content":"\n\n\n\n\n -- Product Candidates with Transformational Potential Highlighted --\n\nCAMBRIDGE, Mass., Jan. 9 /CNW/ -- Vertex Pharmaceuticals\nIncorporated (Nasdaq: VRTX) will today announce its key business objectives\nfor 2006 at the 24th Annual JPMorgan Healthcare Conference in San Francisco.\nThe update will be presented by Joshua Boger, Ph.D., Chairman, President and\nCEO of Vertex Pharmaceuticals. A live webcast of the presentation will be\navailable on Vertex's website, http://www.vrtx.com, at 11:00 a.m. EST, January\n9, 2006. An archived webcast of the presentation will be available on\nVertex's website through January 23, 2006.\n\"In 2005, Vertex achieved all of its clinical, research and business\nobjectives, which created significant value for shareholders,\" stated Joshua\nBoger, Ph.D., Chairman, President and CEO of Vertex Pharmaceuticals. \"Most\nnotably, in 2005 we presented the first clinical results for our HCV protease\ninhibitor VX-950, demonstrating unprecedented antiviral activity. We\nannounced today that we have supported VX-950's early promise with new data\nthat further demonstrate that VX-950 has the potential to transform the future\ntreatment of HCV. We are now prepared to begin clinical trials that may\nestablish the ability of VX-950 to achieve sustained viral responses in HCV\npatients in as little as three months of treatment.\"\n\"In addition to VX-950, we have a broad pipeline of potentially\nbreakthrough drug candidates in development, including compounds targeting\nrheumatoid arthritis, cystic fibrosis, cancer, pain and HIV,\" continued Dr.\nBoger. \"In 2006, we expect to gain important clinical data that could define\nthe medical and commercial opportunities for these product candidates,\nbuilding further value in our pipeline.\"\n\"Vertex is focused on the clinical advancement of our proprietary product\npipeline. Our business model is designed to enable us to achieve our\nobjective of commercializing Vertex-discovered drug candidates both\nindependently and in collaboration with pharmaceutical companies,\" continued\nDr. Boger. \"If we look ahead to the end of the year, we envision that VX-950\nwill be on a registration track with a timetable to commercialization in the\nU.S. and Europe; that we will have a robust and more advanced pipeline of drug\ncandidates with breakthrough potential; and...